Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

24-month Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg and 1.25 mg Fingolimod (FTY720) Administered Orally Once Daily Versus Placebo in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase

NCT00355134 is registered in ClinicalTrials.gov with Novartis as lead sponsor.

NCT NCT00355134
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00355134 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
24-month Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg and 1.25 mg Fingolimod (FTY720) Administered Orally Once Daily Versus Placebo in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase
Lead sponsor
Novartis
Phase
Phase 3
Overall status
Completed
Start date
June 30, 2006
Completion date
August 31, 2011
Enrollment
1,083 (actual)
Sites
112

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis